Nirox (Roxithromycin)

Roxithromycin, the active ingredient in Nirox, is a macrolide antibiotic presented as an oral tablet for oral administration. It is indicated for the treatment of various bacterial infections such as community‑acquired pneumonia, acute bacterial sinusitis, pharyngitis, bronchitis and skin and soft‑tissue infections in adult patients.

GNH USA supplies Nirox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory‑aligned distribution for global markets. All batches are manufactured under GMP conditions and undergo rigorous quality testing before release.

Roxithromycin is used to treat bacterial infections affecting the respiratory tract and skin by targeting susceptible organisms.

- Community-acquired pneumonia: effective in eradicating the causative bacteria and improving clinical symptoms. - Acute bacterial sinusitis: reduces sinus inflammation and clears infection caused by susceptible strains. - Pharyngitis: alleviates sore throat and eliminates bacterial pathogens. - Bronchitis: helps resolve bacterial bronchial infection and associated cough. - Skin and soft tissue infections: treats cellulitis and other bacterial skin conditions.

Roxithromycin may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild stomach upset often reported. - Diarrhea: loose stools that may be self‑limiting. - Abdominal pain: crampy discomfort in the stomach area. - Taste disturbance: altered or metallic taste sensation. - Headache: mild to moderate head pain. - Vomiting: occasional episodes of emesis.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Hepatotoxicity: elevated liver enzymes or jaundice. - Cardiac effects: QT interval prolongation leading to arrhythmia. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Stevens‑Johnson syndrome: rare skin blistering and mucosal involvement.

Before prescribing Roxithromycin, clinicians should consider several precautionary measures to ensure safe use. - Assess renal and hepatic function: adjust use if impairment is present. - Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. - Use with caution in patients with QT prolongation risk: evaluate cardiac history. - Avoid in individuals with known macrolide hypersensitivity: consider alternative agents. - Review concomitant medications: check for potential drug‑drug interactions. - Store at ambient temperature: keep in original packaging, protect from moisture.

Roxithromycin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Co‑administration with drugs that prolong QT interval (e.g., pimozide, cisapride): may increase risk of arrhythmia. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): can raise roxithromycin plasma levels. - Anticoagulants such as warfarin: may enhance anticoagulant effect and bleeding risk.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates (e.g., statins, calcium channel blockers): may have altered concentrations. - Antacids containing aluminum or magnesium: can reduce roxithromycin absorption. - Oral contraceptives: possible reduction in contraceptive efficacy, advise additional protection.